{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:46Z","timestamp":1792644106322,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474134"],"award-info":[{"award-number":["82474134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012131","name":"Department of Science & Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2026-BS-0491"],"award-info":[{"award-number":["2026-BS-0491"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012131","name":"Department of Science & Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2024-BSLH-146"],"award-info":[{"award-number":["2024-BSLH-146"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119356","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:35:39Z","timestamp":1790033739000},"page":"119356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Investigating the anti-TNBC potential of new quinazoline-based PAK4 inhibitors: design, synthesis and biological evaluation"],"prefix":"10.1016","volume":"320","author":[{"given":"Shuang","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-fan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-chen","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-guang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-han","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-hao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-yin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-7652","authenticated-orcid":false,"given":"Fan-hao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejmech.2026.119356_bib1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-021-00415-4","article-title":"New targets in triple-negative breast cancer","volume":"21","author":"Copeland","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"29","key":"10.1016\/j.ejmech.2026.119356_bib2","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1200\/JCO.2005.03.3845","article-title":"Molecular classification and molecular forecasting of breast cancer: ready for clinical application?","volume":"23","author":"Brenton","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119356_bib3","first-page":"523","article-title":"Triple-negative breast cancer on the rise: Breakthroughs and beyond","volume":"17","author":"Agelidis","year":"2025","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119356_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119356_bib5","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.3390\/cancers15153801","article-title":"Systemic therapy for metastatic triple negative breast cancer: current treatments and future directions","volume":"15","author":"Morrison","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119356_bib6","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119356_bib7","article-title":"Translational drugs targeting cancer stem cells in triple-negative breast cancer","volume":"33","author":"Oliveira","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.ejmech.2026.119356_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215813","article-title":"PAK4 in cancer development: emerging player and therapeutic opportunities","volume":"545","author":"Yuan","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119356_bib9","doi-asserted-by":"crossref","DOI":"10.4161\/sgtp.28003","article-title":"P21 activated kinases: structure, regulation, and functions","volume":"5","author":"Rane","year":"2014","journal-title":"Small GTPases"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119356_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2008.06.002","article-title":"UnPAKing the class differences among p21-activated kinases","volume":"33","author":"Eswaran","year":"2008","journal-title":"Trends Biochem. Sci."},{"issue":"4\u20135","key":"10.1016\/j.ejmech.2026.119356_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejcb.2013.03.002","article-title":"P21-activated kinase 4--not just one of the PAK","volume":"92","author":"Dart","year":"2013","journal-title":"Eur. J. Cell Biol."},{"issue":"24","key":"10.1016\/j.ejmech.2026.119356_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413443","article-title":"Regulation of cancer metastasis by PAK2","volume":"25","author":"Wu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119356_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53665-6","article-title":"PAK1, PAK1\u039415, and PAK2: similarities, differences and mutual interactions","volume":"9","author":"Grebe\u0148ov\u00e1","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119356_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4161\/cl.21171","article-title":"PAK4-6 in cancer and neuronal development","volume":"2","author":"Minden","year":"2012","journal-title":"Cell. Logist."},{"key":"10.1016\/j.ejmech.2026.119356_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106207","article-title":"PAK-dependent regulation of actin dynamics in breast cancer cells","volume":"146","author":"Best","year":"2022","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119356_bib16","doi-asserted-by":"crossref","first-page":"17573","DOI":"10.18632\/oncotarget.7466","article-title":"Activated-PAK4 predicts worse prognosis in breast cancer and promotes tumorigenesis through activation of PI3K\/AKT signaling","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119356_bib17","first-page":"3026","article-title":"PAK4 enhances TGF-\u03b21-induced epithelial-mesenchymal transition through activating \u03b2-catenin signaling pathway in renal tubular epithelial cells","volume":"11","author":"Fan","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119356_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12935-025-04042-z","article-title":"P21-activated kinase 4: a potent oncogene, molecular mechanisms and opportunities for targeted therapy","volume":"25","author":"Huang","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119356_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/0008-5472.CAN-18-2575","article-title":"PAK4 phosphorylates fumarase and blocks TGF\u03b2-Induced cell growth arrest in lung cancer cells","volume":"79","author":"Chen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119356_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121263","article-title":"Pan-cancer analysis identifies the immunological and prognostic role of PAK4","volume":"312","author":"Tang","year":"2023","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119356_bib21","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ygeno.2020.01.016","article-title":"Systemic analysis of the expression and prognostic significance of PAKs in breast cancer","volume":"112","author":"Dang","year":"2020","journal-title":"Genomics"},{"issue":"17","key":"10.1016\/j.ejmech.2026.119356_bib22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3390\/cells13171444","article-title":"PAK4 is involved in the stabilization of PD-L1 and the resistance to doxorubicin in osteosarcoma and predicts the survival of diagnosed patients","volume":"13","author":"Zhang","year":"2024","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119356_bib23","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.3390\/ijms26083885","article-title":"The role of the p21-Activated kinase family in tumor immunity","volume":"26","author":"Lu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119356_bib24","doi-asserted-by":"crossref","first-page":"9446","DOI":"10.1073\/pnas.0911863107","article-title":"Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth","volume":"107","author":"Murray","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119356_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41420-025-02677-5","article-title":"Multi-omics analysis reveals RNA polymerase II degradation as a novel mechanism of PF-3758309's anti-tumor activity","volume":"11","author":"Jia","year":"2025","journal-title":"Cell Death Discov."},{"issue":"25","key":"10.1016\/j.ejmech.2026.119356_bib26","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1038\/onc.2013.296","article-title":"PAK4 kinase-mediated SCG10 phosphorylation involved in gastric cancer metastasis","volume":"33","author":"Guo","year":"2014","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119356_bib27","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543776.2021.1944100","article-title":"Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review","volume":"31","author":"Wang","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119356_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/ijms17040470","article-title":"GL-1196 suppresses the proliferation and invasion of gastric cancer cells via targeting PAK4 and inhibiting PAK4-Mediated signaling pathways","volume":"17","author":"Zhang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119356_bib29","first-page":"2736","article-title":"LC-0882 targets PAK4 and inhibits PAK4-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells","volume":"9","author":"Zhang","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119356_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11523-026-01206-3","article-title":"First-in-Human phase I study of KPT-9274, a first-in-class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies","volume":"21","author":"Razak","year":"2026","journal-title":"Target Oncol"},{"issue":"18","key":"10.1016\/j.ejmech.2026.119356_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251810138","article-title":"Inhibition of NAMPT by PAK4 inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"41","key":"10.1016\/j.ejmech.2026.119356_bib32","doi-asserted-by":"crossref","first-page":"43853","DOI":"10.18632\/oncotarget.6081","article-title":"p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells","volume":"6","author":"Zhuang","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119356_bib33","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1021\/jm401768t","article-title":"Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1\/2 kinase inhibitors","volume":"57","author":"Staben","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119356_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111878","article-title":"Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor","volume":"186","author":"Guo","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119356_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1021\/acs.jmedchem.7b01342","article-title":"Structure-based design of 6-Chloro-4-aminoquinazoline-2-carboxamide derivatives as potent and selective p21-Activated kinase 4 (PAK4) inhibitors","volume":"61","author":"Hao","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119356_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116971","article-title":"Design, synthesis and biological evaluation of novel benzimidazole-derived p21-activited kinase 4 (PAK4) inhibitors bearing a 4-(4-methylpiperazin-1-yl)phenyl scaffold as potential antitumor agents","volume":"280","author":"Hao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119356_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107686","article-title":"Design, synthesis and biological evaluation of novel quinazoline-derived EGFR\/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents","volume":"151","author":"Hao","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119356_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/open.202400197","article-title":"New tricyclic aryl quinazoline derivatives by suzuki-miyaura cross-coupling","volume":"13","author":"Elmuradov","year":"2024","journal-title":"ChemistryOpen"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119356_bib39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4143\/crt.2014.054","article-title":"p21-activated kinase 4 (PAK4) as a predictive marker of gemcitabine sensitivity in pancreatic cancer cell lines","volume":"47","author":"Mo9on","year":"2014","journal-title":"Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119356_bib40","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/cancers12061489","article-title":"c-Src and EGFR inhibition in molecular cancer therapy: what else can we improve?","volume":"12","author":"Belli","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.ejmech.2026.119356_bib41","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-16-3138","article-title":"Dual inhibition of EGFR and c-Src by cetuximab and dasatinib combined with FOLFOX chemotherapy in patients with metastatic colorectal cancer","volume":"23","author":"Parseghian","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119356_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.602900","article-title":"c-Src increases the sensitivity to TKIs in the EGFR-mutant lung adenocarcinoma","volume":"11","author":"Min","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119356_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2026.118637","article-title":"Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation","volume":"137","author":"Hao","year":"2026","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119356_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090758","article-title":"ROCK1 deficiency enhances protective effects of antioxidants against apoptosis and cell detachment","volume":"9","author":"Surma","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119356_bib45","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/jcb.26103","article-title":"Measuring kinase Activity-A global challenge","volume":"118","author":"Cann","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2026.119356_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-1-61779-012-6_9","article-title":"Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability","volume":"716","author":"Sylvester","year":"2011","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119356_bib47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/ci500681r","article-title":"DOCKTITE-a highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment","volume":"55","author":"Scholz","year":"2015","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119356_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nprot.2007.30","article-title":"In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro","volume":"2","author":"Liang","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2026.119356_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-1-0716-3052-5_22","article-title":"Transwell in vitro cell migration and invasion assays","volume":"2644","author":"Justus","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119356_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4939-2742-5_9","article-title":"The Western blot","volume":"1318","author":"Hnasko","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119356_bib51","first-page":"301","article-title":"Analysis of cell cycle by flow cytometry","volume":"281","author":"Pozarowski","year":"2004","journal-title":"Methods Mol. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119356_bib52","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot087288","article-title":"Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry","volume":"2016","author":"Crowley","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"issue":"37","key":"10.1016\/j.ejmech.2026.119356_bib53","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1038\/onc.2016.261","article-title":"A novel interaction of PAK4 with PPAR\u03b3 to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma","volume":"36","author":"Kesanakurti","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119356_bib54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-60761-849-2_4","article-title":"Histopathology procedures: from tissue sampling to histopathological evaluation","volume":"691","author":"Slaoui","year":"2011","journal-title":"Methods Mol. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:23:21Z","timestamp":1792643001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":54,"alternative-id":["S0223523426008019"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119356","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the anti-TNBC potential of new quinazoline-based PAK4 inhibitors: design, synthesis and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119356"}}